Sun Pharma's non-binding offer in January led to advanced funding talks; acquisition would expand women's health and biosimilars presence. Chairman Dilip Shanghvi eyes innovative research alongside generics strength. Intraday drop of 4.13%; broader pharma selloff amid US tariff jitters. Trading near the 52-week low of ₹1,480, with mcap pressure from volatility.

#FundamentalViews#WatchOutFor#StockInNews

964 likes·45 comments